- Home
- EIX vs ONC Comparison
EIX vs ONC Comparison
Compare EIX & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIX | ONC |
|---|---|---|
| Founded | 1886 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8B | 33.5B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | EIX | ONC |
|---|---|---|
| Price | $70.73 | $277.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $69.20 | ★ $377.91 |
| AVG Volume (30 Days) | ★ 2.9M | 240.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | ★ 248.94 | N/A |
| EPS | ★ 11.55 | N/A |
| Revenue | ★ $19,317,000,000.00 | N/A |
| Revenue This Year | N/A | $759.19 |
| Revenue Next Year | $3.01 | $14.51 |
| P/E Ratio | ★ $6.17 | $614.06 |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $47.73 | $196.53 |
| 52 Week High | $75.50 | $385.22 |
Technical Indicators
Market Signals| Indicator | EIX | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 33.37 |
| Support Level | $69.14 | $239.25 |
| Resistance Level | $74.71 | $284.51 |
| Average True Range (ATR) | 1.53 | 6.45 |
| MACD | -0.48 | -0.10 |
| Stochastic Oscillator | 36.68 | 14.77 |
Price Performance
Historical ComparisonAbout EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.